Syndax’s Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the best stocks to buy under $20. On September 19, Syndax Pharmaceuticals announced a major milestone: the National Comprehensive Cancer ...

Long-term analysis finds disease risk, not remission status, determines transplant outcomes in acute myeloid leukemia

Results of a recently published long-term follow-up of the ASAP trial, which was conducted at universities and clinics across ...

Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute ...

The Company has submitted a supplemental New Drug Application (sNDA) seeking the approval of revumenib for the treatment of R/R mNPM1 AML. The sNDA has been granted Priority Review by the FDA and ...
mskcc.org

New Type of CAR T Cells Successfully Target AML in Pilot Study

Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...